These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31870830)

  • 1. Gut microbiota; an overlooked effect of phosphate binders.
    Rahbar Saadat Y; Niknafs B; Hosseiniyan Khatibi SM; Ardalan M; Majdi H; Bahmanpoor Z; Abediazar S; Zununi Vahed S
    Eur J Pharmacol; 2020 Feb; 868():172892. PubMed ID: 31870830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
    Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins.
    Laville SM; Massy ZA; Kamel S; Chillon JM; Choukroun G; Liabeuf S
    Toxins (Basel); 2021 Jan; 13(2):. PubMed ID: 33530404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
    Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
    Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate, Microbiota and CKD.
    Favero C; Carriazo S; Cuarental L; Fernandez-Prado R; Gomá-Garcés E; Perez-Gomez MV; Ortiz A; Fernandez-Fernandez B; Sanchez-Niño MD
    Nutrients; 2021 Apr; 13(4):. PubMed ID: 33924419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut Microbiome-Derived Uremic Toxin Levels in Hemodialysis Patients on Different Phosphate Binder Therapies.
    Wang LC; Tapia LM; Tao X; Chao JE; Thwin O; Zhang H; Thijssen S; Kotanko P; Grobe N
    Blood Purif; 2022; 51(8):639-648. PubMed ID: 34375976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
    Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
    JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
    Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
    Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin and Chronic Kidney Disease.
    Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
    J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M; Papachristou E; Goumenos DS
    Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphate management in chronic kidney disease.
    Bhan I
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
    Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
    Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral phosphate binders in CKD - is calcium the (only) answer?
    Goldsmith D; Covic A
    Clin Nephrol; 2014 Jun; 81(6):389-95. PubMed ID: 25017668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.